ライフサイエンスコーパス: entecavir

1 e of ARC-520 and daily nucleosidic analogue (entecavir).

2 ith a high barrier to resistance (tenofovir, entecavir).

3 ting anti-HBV compounds such as tenofovir or entecavir.

4 wed by 40 weeks of combined peginteferon and entecavir.

5 ing pocket for a known anti-HBV drug, namely entecavir.

6 75 patients, 82% Asian, and 55% treated with entecavir.

7 mtricitabine, tenofovir, and, more recently, entecavir.

8 ents showed that M184V confers resistance to entecavir.

9 efovir 15% (5 of 33), tenofovir 0% (0 of 3), entecavir 0% (0 of 1), and 5% (1 of 20) for those not gi

10 eAg-positive CHB patients were randomized to entecavir 0.5 mg (n = 354) or lamivudine 100 mg (n = 355

11 N) (male: <= 45, female: <= 30 U/L) received entecavir 0.5 mg daily for 8 weeks followed by the addit

12 hen continued with long-term NA prophylaxis (entecavir: 8, tenofovir: 20 patients).

13 Entecavir, a drug approved by the Food and Drug Administ

14 Birinapant enhances the ability of entecavir, an antiviral nucleoside analog, to reduce vir

15 We evaluated continued entecavir and lamivudine treatment through 96 weeks.

16 Conclusion: The combination of entecavir and peginterferon for up to 48 weeks rarely le

17 mine the safety and efficacy of therapy with entecavir and peginterferon in a group of children in th

18 he safety and efficacy of the combination of entecavir and peginterferon in adults in the IT phase of

19 Overall, both entecavir and tenofovir alafenamide have similar impacts

20 ng-term viral suppression can be obtained by entecavir and tenofovir even in cases of multidrug resis

21 Entecavir and tenofovir were shown to be effective in su

22 of nucleos(t)ide analogs and agents such as entecavir and tenofovir with high potency and high genet

23 a high genetic barrier to resistance, namely entecavir and tenofovir, has improved the efficacy of an

24 All patients were commenced on entecavir and/or tenofovir.

25 nts including tenofovir disoproxil fumarate, entecavir, and telbivudine offer greater potency than la

26 ocumented HBV reactivation were treated with entecavir at a dosage of 0.5 mg/day for 48 weeks.

27 s who were NA-treated receiving tenofovir or entecavir at baseline, week 48, and week 96.

28 Entecavir (BMS-200475) was synthesized from 4-trimethyls

29 ding the clinical efficacy of switching from entecavir-brand-name drugs (ETV-Brand) to entecavir gene

30 Entecavir can be given safely for a short time and cause

31 1-resistance patterns and their selection by entecavir, caution is needed with the use of entecavir i

32 In the entecavir cohort, 2 (1.37%) of 145 patients experienced

33 eron, adefovir monotherapy and adefovir plus entecavir combination.

34 Entecavir demonstrated superior benefit to lamivudine at

35 with reduced viremia after administration of entecavir, developed polyfunctional, HBV-specific CD8(+)

36 The combined single dose ARC-520 and entecavir effect on HBV DNA was constant over time, with

37 verse transcriptase (RT) inhibitors, such as entecavir (ETV) and lamivudine (3TC), serve as crucial a

38 BACKGROUND & AIMS: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF)

39 3 years of therapy with telbivudine (LdT) or entecavir (ETV) and to assess predictive factors for eGF

40 omly assigned to receive either prophylactic entecavir (ETV) before chemotherapy to 3 months after co

41 BACKGROUND/AIMS: Entecavir (ETV) can suppress chronic hepatitis B (CHB) v

42 Entecavir (ETV) is a guanosine nucleoside analogue with

43 Entecavir (ETV) is a potent inhibitor of hepatitis B vir

44 The novel 2'-deoxyguanosine analog Entecavir (ETV) is a potent inhibitor of hepatitis B vir

45 Entecavir (ETV) is a widely used anti-hepatitis B virus

46 side analog inhibitor of viral DNA synthesis entecavir (ETV) reduced hepatocyte turnover during clear

47 Entecavir (ETV) resistance (ETVr) results from HBV rever

48 Virologic resistance emerging during entecavir (ETV) therapy for hepatitis B virus (HBV) requ

49 ic hepatitis B (CHB) patients, who underwent entecavir (ETV) treatment.

50 ic antiviral resistance was performed on 673 entecavir (ETV)-treated nucleoside naive hepatitis B vir

51 onic hepatitis B (CHB) patients treated with entecavir (ETV).

52 Entecavir (ETV; Baraclude) is a novel deoxyguanosine ana

53 had previously been treated with 8 weeks of entecavir followed by 40 weeks of combined peginteferon

54 Conclusion: A lead-in strategy of 8 weeks of entecavir followed by combination peginterferon and ente

55 tion of peginterferon alfa-2a 180 ug/week to entecavir for an additional 40 weeks.

56 om entecavir-brand-name drugs (ETV-Brand) to entecavir generic drugs (ETV-Generic) with 0.5 mg once d

57 decrease of 8 mL/min/1.73 m2 occurred in the entecavir group (p < 0.001).

58 nfections numerically, whereas tenofovir and entecavir had no cases and may be more effective, but th

59 Cutaneous adverse reaction associated with entecavir has rarely been reported in literature.

60 comparatively high and both telbivudine and entecavir have decreased efficacy against lamivudine-res

61 ore potent nucleoside analogs (tenofovir and entecavir) have proven to have much lower rates of antiv

62 nal safety between tenofovir alafenamide and entecavir; however, the relatively small sample size and

63 his study was to investigate the efficacy of entecavir in chronic hepatitis D (CHD).

64 entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who

65 ge, this case was the first case reported on entecavir induced lichenoid drug eruption.

66 Entecavir is a nucleoside analog with potent antiviral e

67 Entecavir is a potent antiviral agent with a low rate of

68 Entecavir is a potent antiviral for nucleoside-naive pat

69 Entecavir is a potent oral antiviral agent of high genet

70 e obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replica

71 Although entecavir is approved and recommended for children aged

72 nucleos(t)ide analogue agents, tenofovir and entecavir, is a crucial intervention that supports the g

73 We observed that entecavir led to a consistent 1-log(10) decrease in HIV-

74 The observed continuous HBV DNA decline is entecavir mediated, the strong but transient HBsAg and H

75 The peginterferon and entecavir monotherapy groups also differed in HCC incide

76 Long-term entecavir monotherapy is highly effective at preventing

77 alysis showed that in one of these patients, entecavir monotherapy led to an accumulation of HIV-1 va

78 s B liver transplant recipients treated with entecavir monotherapy without hepatitis B immune globuli

79 In patients exposed to entecavir (n = 102), full resistance was present in 35.3

80 Patients continuing in year 2 (entecavir, n = 243; lamivudine, n = 164) were assessed f

81 titis B immunoglobulin (HBIG), or lamivudine+entecavir on direct sequencing were cloned after nested

82 atures of chronic hepatitis B (CHB) received entecavir once-daily in a dose of 0.015 mg/kg (0.5 mg ma

83 when reverse transcription was inhibited by entecavir or by the Y63F change in P protein.

84 Control mice were given either entecavir or non-HBV-specific siRNAs and vaccine compone

85 liver transplant recipients receiving either entecavir or tenofovir alafenamide, to assess the effect

86 All of them received either prophylactic entecavir or tenofovir therapy.

87 sis and with chronic hepatitis B who started entecavir or tenofovir treatment with baseline HBV viral

88 HBV nucleos(t)ide analogues, such as entecavir or tenofovir, are ineffective against HDV.

89 resistance as a first-line therapy, such as entecavir or tenofovir, provides the best chance of achi

90 alogues with lower resistance rates, such as entecavir or tenofovir, suppress hepatitis B virus (HBV)

91 n (CHB) with the nucleos(t)ide analogs (NAs) entecavir or tenofovir.

92 h rate of antiviral resistance compared with entecavir or tenofovir.

93 This study assessed a pilot study of entecavir plus low-dose, on-demand HBIg in preventing HB

94 Entecavir plus low-dose, on-demand HBIg resulted in a lo

95 ents undergoing HBV-related LT and receiving entecavir plus low-dose, on-demand HBIg were enrolled an

96 Surprisingly, during entecavir plus tenofovir combination, anti-HBe seroconve

97 ate insurance examines trends in the cost of entecavir prescribed for chronic hepatitis B treatment.

98 Giving the mice the nucleoside analogue entecavir reduced viral loads and decreased liver inflam

99 nt experienced virologic breakthrough due to entecavir resistance.

100 esistance mutation V173L (in 5 samples), the entecavir-resistance mutations T184S (in 2 samples) and

101 ults with combined peginterferon alfa-2a and entecavir results in a decline in serum HBeAg and HBsAg

102 Although entecavir showed more favorable effects on total cholest

103 purine analogs, nelarabine, fludarabine, and entecavir, showing the suppression of HIV-1 expression f

104 Entecavir successfully suppressed HBV DNA to undetectabl

105 ucleotide analogs, lamivudine, adefovir, and entecavir, suppress HBV replication and are extremely we

106 assessed the HCC incidence beyond year 5 of entecavir/tenofovir (ETV/TDF) therapy and tried to deter

107 notolerant trial participants on PegIFNalpha/entecavir therapy and 88 immune active trial participant

108 ir followed by combination peginterferon and entecavir therapy for 40 weeks had limited efficacy in a

109 ectrum of cutaneous drug reaction related to entecavir therapy.

110 Similar proportions of entecavir-treated and lamivudine-treated patients achiev

111 cing of the viral genome was performed on 11 entecavir-treated and pegylated interferon (peginterfero

112 enofovir-treated and 25.7% patients who were entecavir-treated had unquantifiable HBV RNA (P > 0.05).

113 Viral loads of entecavir-treated patients were constantly suppressed to

114 ntigen truncation mutations were detected in entecavir-treated patients with HCC but not in peginterf

115 P = .022 for comparison of peginterferon- vs entecavir-treated patients).

116 Higher proportions of entecavir-treated than lamivudine-treated patients achie

117 rmed HBeAg seroconversion occurred in 31% of entecavir-treated versus 25% of lamivudine-treated patie

118 Among patients treated in year 2, 74% of entecavir-treated versus 37% of lamivudine-treated patie

119 polymerase chain reaction (PCR), and 79% of entecavir-treated versus 68% of lamivudine-treated patie

120 One year of entecavir treatment is ineffective in CHD.

121 Entecavir treatment through 96 weeks results in continue

122 We demonstrated that in 2 PXB-mice after entecavir treatment, the total cccDNA content did not ch

123 CD38+ MAIT cells in blood, which declined on entecavir treatment.

124 Nine patients were sampled before and on entecavir treatment.

125 t of normal) occurred in 4 patients, despite entecavir treatment.

126 Structural comparison with the DNA:dGTP/entecavir-triphosphate complex also indicated that the c

127 dy in chimeric mice harboring the lamivudine/entecavir triple mutant, FMCAP effectively reduced HBV v

128 ated significant activity against lamivudine/entecavir triple mutants (L180M + S202G + M204V).

129 0M/rtM204V) mutants as well as in lamivudine/entecavir triple mutants (L180M+S202G+M204V) in vitro.

130 patitis B e antibody and about the safety of entecavir versus tenofovir.

131 Entecavir was associated with a more favorable lipid pro

132 s prior to his consultation, antiviral agent entecavir was commenced for his chronic hepatitis B infe

133 Entecavir was given at a dosage of 1 mg/d for 1 year.

134 AP effectively reduced HBV viral load, while entecavir was not effective.

135 lthcare visits and that generic tenofovir or entecavir would be dispensed for treatment.